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Chronic cardiac loading as occurs during long-
standing hypertension induces cardiac hyper-
trophy, which often progresses to left ventricle 
(LV) dysfunction and overt heart failure (HF). 
The molecular changes that precede and herald 
this transition from hypertrophy toward HF are 
incompletely understood (1).
The intercalated disc (ID) of cardiac myo-
cytes has emerged as a crucial structure in the 
heart. The cardiac ID consists of three major 
structures: gap junctions, adherens junctions, 
and desmosomes. In dilated cardiomyopathy, 
the number of gap junctions is decreased while 
the adherens junctions increase, leading to re-
duced cardiac communication and increased 
stiff  ness (2). An important role for ID structure 
is further demonstrated by the fact that   complete 
loss of ID proteins like N-cadherin, plakoglobin, 
and β-catenin (3–6) is lethal. Moreover, mu-
tations in ID proteins like desmoplakin, desmo-
globin, plakoglobin, and plakophilin-2 (7–9) 
cause human cardiomyopathies. However, fac-
tors that more subtly modulate the ID have not 
yet been described.
We have previously reported on the unique 
propensity of the homozygous hypertensive 
transgenic rat TGR(mRen-2) 27 (Ren-2).  A pro-
portion of these rats rapidly progresses toward HF, 
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The intercalated disc (ID) of cardiac myocytes is emerging as a crucial structure in the 
heart. Loss of ID proteins like N-cadherin causes lethal cardiac abnormalities, and muta-
tions in ID proteins cause human cardiomyopathy. A comprehensive screen for novel mech-
anisms in failing hearts demonstrated that expression of the lysosomal integral membrane 
protein 2 (LIMP-2) is increased in cardiac hypertrophy and heart failure in both rat and 
human myocardium. Complete loss of LIMP-2 in genetically engineered mice did not affect 
cardiac development; however, these LIMP-2 null mice failed to mount a hypertrophic 
response to increased blood pressure but developed cardiomyopathy. Disturbed cadherin 
localization in these hearts suggested that LIMP-2 has important functions outside 
lysosomes. Indeed, we also fi  nd LIMP-2 in the ID, where it associates with cadherin. 
RNAi-mediated knockdown of LIMP-2 decreases the binding of phosphorylated 𝗃-catenin 
to cadherin, whereas overexpression of LIMP-2 has the opposite effect.
Collectively, our data show that LIMP-2 is crucial to mount the adaptive hypertrophic 
response to cardiac loading. We demonstrate a novel role for LIMP-2 as an important 
mediator of the ID.
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whereas the other rats remain compensated for a prolonged 
time (10). Obtaining minute LV biopsies in these Ren-2 
rats in an early stage of compensated LV hypertrophy allowed 
us to identify molecular changes that precede the transition to-
ward HF, such as increased expression of thrombospondin 
(TSP)2 and galectin-3 (10, 11). We recently were able to use 
these minute LV biopsies to reliably obtain comprehensive 
gene expression profi  les from the LV. We showed that linear 
amplifi  cation allowed us to retain a highly representative gene 
expression profi  le comparable to that obtained from a whole 
heart homogenate (12). Therefore, obtaining Ren-2 rat LV 
biopsies now allowed us to search in a more comprehensive 
manner for novel molecular mechanisms that precede the 
transition toward HF. We compared gene expression profi  les 
obtained from hypertrophic hearts that either progressed to 
HF or remained compensated. Among the 143 genes that were 
diff  erentially regulated in failure-prone hypertrophied hearts, 
lysosomal integral membrane protein 2 (LIMP-2) was up-
regulated in failure-prone hearts. LIMP-2 was up-regulated 
quickly in the heart upon pressure loading. LIMP-2 KO mice 
lacked a normal hypertrophic response to pressure loading 
with angiotensin (Ang)II, but quickly developed dilated 
cardiomyopathy accompanied by a disturbed structure of the 
ID. In human hearts as well as in cardiac myocytes in vitro, 
LIMP-2 was found to interact with N-cadherin at the site of 
the ID. We propose that LIMP-2 is a novel regulator of the 
cardiac ID, and that it is crucial in the development of adaptive 
cardiac hypertrophy possibly through its eff  ects on the binding 
of the two ID members β-catenin and N-cadherin.
RESULTS
Gene expression profi  le of failure-prone LV hypertrophy
We obtained cardiac biopsies in 10 homozygous Ren-2 rats 
at a stage of compensated LV hypertrophy at 10 wk of age. 
Four rats rapidly progressed toward HF within 5 wk after the 
biopsy was taken, whereas the remaining six rats remained com-
pensated for 11 wk after biopsy (Fig. 1 A). After linear T7-based 
amplifi  cation and subsequent Aff  ymetrix RAE230 2.0 gene 
expression analysis of these biopsies (GEO accession number 
GSE4286), we identifi  ed 181 diff  erentially expressed genes 
that were up- or down-regulated exclusively in the hypertro-
phied hearts that progressed toward HF (Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20070145/DC1). 
LIMP-2, a lysosomal membrane protein, was one of the up-
regulated mRNAs in HF-prone rats (Fig. 1 B) and is of par-
ticular interest given its ability to interact with TSP1 (13) and 
TSP2 (not depicted), the latter of which we have shown to be 
crucial in the transition from hypertrophy toward HF (10). 
Fig. 1 C shows that LIMP-2 protein also has a role in end-
stage HF in Ren-2 rats.
AngII induces dilated cardiomyopathy in LIMP-2 KO mice
Because loss-of-function mutations in lysosomal proteins 
have been linked to HF (14–16), we further investigated the 
role of LIMP-2 in a mouse model of AngII-induced hyper-
tension. AngII was given subcutaneously for 2 and 4 wk to 
LIMP-2 KO and control mice. AngII treatment resulted in a 
29.8 and 30.2% increase in LV mass index in WT mice after 
2 and 4 wk, respectively, but the hypertrophic response was 
virtually absent in the AngII-treated LIMP-2 KO mice (8.7% 
increase in LV mass index after 2 wk and 13.7% after 4 wk; 
P < 0.01 vs. AngII-treated WT mice; Fig. 2 A and Table S2, 
which is available at http://www.jem.org/cgi/content/full/
jem.20070145/DC1). This was confi  rmed by measurement of 
individual cardiac myocyte area after 4 wk of AngII treatment. 
LV myocyte area was signifi  cantly smaller in AngII-treated 
Figure 1.  Increased expression of LIMP-2 in Ren-2 rats. An LV 
biopsy was taken at 10 wk of age, when Ren-2 rats exhibit comparable 
cardiac hypertrophy (reference 10) and fractional shortening cannot 
distinguish between rats that will progress to HF or those that will stay 
compensated (A). Between 15 and 18 wk of age, part of the Ren-2 rats 
progressed to HF, whereas the remainder stayed compensated until they 
were killed at 21 wk of age *, P < 10−5. In 10-wk-old hypertrophic Ren-2 
rats, microarray analysis showed specifi  c overexpression of LIMP-2 mRNA 
in failure-prone rats (HF-prone LVH; n = 4) as compared with the hyper-
trophied hearts that remained compensated (comp LVH; n = 6) and to 
controls (n = 4) (B). LIMP-2 protein was up-regulated in end-stage failing 
Ren-2 rats (HF; n = 9) as compared with compensated Ren-2 rats (comp; 
n = 6) and control rats (n = 6) (C). *, P < 0.05 versus control; **, P < 0.01 
versus control; $, P < 0.05 versus comp; Mwm, molecular weight 
marker; au, arbitrary units.JEM VOL. 204, May 14, 2007  1229
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KO mice than in AngII-treated WT controls (myocyte area 
in arbitrary units: 264 ± 42 in AngII-treated KO mice vs. 
308 ± 14 in AngII-treated WTs; P < 0.01). In addition, 
although AngII induced comparable increases in perivascular 
fi  brosis in LIMP-2 KO and WT mice (not depicted), 4 wk of 
AngII treatment induced a massive interstitial fi  brotic  re-
sponse in the LVs of LIMP-2 KO mice as opposed to WT 
control littermates (interstitial fi  brosis: 15.0 ± 6.0% in AngII-
treated KO mice vs. 3.8 ± 1.7% in AngII-treated controls; 
P < 0.05; Fig. 3). This increased interstitial fi  brosis in AngII-
treated KO mice did not occur after 2 wk of AngII treatment 
(interstitial fi  brosis: 4.7 ± 1.1% in AngII-treated KO mice vs. 
4.8 ± 1.6% in AngII-treated controls; Fig. 3). Immunohisto-
chemical staining for desmin showed altered internal archi-
tecture of cardiac myocytes in AngII-treated LIMP-2 null 
mice (Fig. 4 and Fig. S1).
We ensured that AngII induced a similar blood pressure 
response in both WT and KO mice (Fig. 2 B). Despite de-
creased LV hypertrophy, LIMP-2 null mice demonstrated a 
normal response of the classical markers for hypertrophy 
brain natriuretic peptide (BNP) and atrial natriuretic factor 
(ANF; Fig. 2 C), suggesting that the hypertrophic gene ex-
pression program was normally initiated upon AngII treatment. 
In contrast, the structural cellular hypertrophy marker α-
skeletal actin (aska) was induced to a signifi  cantly lesser extent 
in AngII-treated LIMP-2 KOs as compared with AngII-treated 
Figure 2.  AngII treatment in LIMP-2 KO (KO Ang) mice induces 
dilated cardiomyopathy. AngII increased LV weight and myocyte area in 
WT mice (n = 14) but not in KO mice (n = 14; *, P < 0.01 versus WT; 
n = 8) (A). Bars, 50 μm. LIMP-2 KO (n = 3) and WT (n = 4) mice showed 
comparable blood pressure responses to AngII (B). BNP, ANF, and aska 
mRNAs were induced in WT Ang and KO Ang (*, P < 0.05 vs. baseline; 
n = 4), but aska to a signifi  cantly lesser extend in KO Ang ($, P < 0.05 vs. 
WT Ang) (C). Echocardiography shows hypertrophied LV walls in WT Ang 
at days 14 and 28, whereas KOs did not show hypertrophy but were di-
lated (*, P < 0.005 vs. baseline and KO Ang; $, P < 0.005 vs. baseline and 
WT Ang; all groups, n ≥ 9) (D). β-adrenergic response to dobutamin was 
decreased in KO Ang mice (WT and KO, n = 4; WT Ang, n = 14; KO Ang, 
n = 9; *, P < 0.005) (E). LVW/BW, LV weight corrected for body weight.
Figure 3.  After 4 wk of AngII treatment, LIMP-2 KO mice have 
massive interstitial fi  brosis. Sirius red staining of LVs of 4-wk AngII-
treated LIMP-2 KO (n = 4) and WT (n = 5) mice shows marked interstitial 
fi  brosis in KO mice (*, P < 0.02 vs. WT Ang and KO baseline). The overview 
shows that this fi  brosis was not uniformly distributed, but patchy. After 
2 wk of AngII treatment, LIMP-2 KO and WT mice have similar induction 
of interstitial fi  brosis, suggesting that the massive fi  brosis after 4 wk is 
secondary. Both KO and WT mice treated with AngII show a similar degree 
of perivascular fi  brosis. Bars, 250 μm.1230  LIMP-2 CRUCIAL TO PREVENT CARDIOMYOPATHY | Schroen et al.
WTs (Fig. 2 C), refl  ecting the reduced size of cardiac myo-
cytes (17). Serial echocardiography revealed that AngII in-
duced signifi  cant cardiac dilation in AngII-treated LIMP-2 
null mice already after 7 d, whereas AngII-treated WTs 
showed concentric LV hypertrophy without dilation (Fig. 2 D 
and Table S2). In addition, AngII induced loss of contrac-
tile reserve in LIMP-2 null mice as demonstrated by a re-
duced baseline pressure in the LV already after 2 wk of AngII 
treatment (Table S2) and a reduced inotropic response to do-
butamine infusion after 4 wk (+dP/dt/peak systolic P 79.8/s ± 
5.1 in AngII-treated KO mice vs. 100.0/s ± 4.0 in AngII-
treated controls; P < 0.005; Fig. 2 E).
Collectively, in LIMP-2 null mice, hypertension did not 
induce the normal hypertrophic response but rather dilated 
cardiomyopathy with secondary reactive interstitial fi  brosis 
and loss of cardiac function.
LIMP-2 expression is regulated by cardiac stress
That AngII-treated LIMP-2 null mice failed to mount a hyper-
trophic response, yet normally induced expression of BNP and 
ANF, suggested that LIMP-2 plays a crucial role in the normal 
response to mechanical loading. In line with this, we show that 
LIMP-2 expression increased signifi  cantly after cardiac myo-
cyte stretch in vitro (Fig. 5 A). This was also seen in vivo in 
  exercise-induced physiological hypertrophy (Fig. 5 B). LIMP-2 
expression increased upon pressure loading by transverse aortic 
binding (Fig. 5 C). The increase in LIMP-2 occurred rapidly as 
LIMP-2 expression increased already after 1 h of transverse 
aortic binding, which shows that LIMP-2 is an early responder 
to cardiac loading. To assess whether LIMP-2 is also involved 
in the human response to cardiac pressure loading, we analyzed 
the expression of LIMP-2 by quantitative RT-PCR in cardiac 
biopsies of 20 aortic stenosis patients with overt cardiac hyper-
trophy and seven controls. This experiment showed a signifi  -
cant LIMP-2 up-regulation in the hypertrophic hearts of aortic 
stenosis patients as compared with controls (Fig. 5 D).
LIMP-2 is present at the cardiac ID
We next analyzed the expression pattern of LIMP-2 in pressure-
overloaded murine myocardium by  immunohistochemistry. 
The protein is expressed, as expected, in intracellular   vacuole-
shaped compartments of cardiac myocytes and endothelial 
cells, but we also found it atypically distributed on the plasma 
membrane of cardiac myocytes (Fig. 6 A). Immuno-electron 
microscopy confi  rmed this fi  nding (Fig. 6 B). Strikingly, 
electron microscopy of AngII-treated LIMP-2 KO and 
control LV sections revealed abnormal morphology of the 
ID in LIMP-2 null mice, suggesting that LIMP-2 may be 
  involved in normal ID biology. At cell–cell contacts, the 
membrane at the AngII-treated KO ID showed a signifi  cantly 
higher degree of convolution (Fig. 6, C and D), indicative of 
disturbed ID architecture (2). Because alterations in the ID 
have been shown to cause dilated cardiomyopathy (2, 18), we 
surmised that LIMP-2 may be crucial for proper functioning 
of the ID. Immunoprecipitation (IP) of neonatal rat cardiac 
myocyte protein showed that LIMP-2 physically interacts 
with N-cadherin, a vital constituent of adherens junctions 
(Fig. 7 A). We translated this fi  nding to the human situation, 
as confocal microscopy of control as well as failing human 
myocardium confi  rmed the interaction between cadherin 
and LIMP-2 and showed that this interaction takes place at 
the site of the ID, where cadherin and LIMP-2 colocalize 
Figure 4.  AngII-treated LIMP-2 KO mice have a disturbed internal 
architecture. Desmin-stained cardiac myocytes of AngII-treated LIMP-2 
KO mice have a disturbed internal structure, as shown by the higher and 
more capricious desmin expression in these mice. In AngII-treated KO 
mice, fi  brotic areas were not taken into account because here myocyte 
suffering is evident. Bars, 250 μm.
Figure 5.  LIMP-2 expression is up-regulated in other forms of 
mechanical loading. In neonatal rat cardiac myocytes, 6 h of stretch 
elevated LIMP-2 mRNA expression (n = 4 per group) (a). LIMP-2 expres-
sion was also up-regulated in hypertrophic myocardium from rats that 
had undergone exercise training for 10 wk (5 d per week; n = 6) as com-
pared with nonhypertrophic control rats (n = 7) (b). After 1 h of trans-
verse aortic banding in mice, LIMP-2 protein is elevated (c). LIMP-2 mRNA 
is up-regulated in hypertrophic patients with aortic stenosis (LVH; n = 20) 
as compared with nonhypertrophic control patients (n = 7) (d). *, P < 0.05 
versus control; **, P < 0.01 versus control; LVH; LV hypertrophy.JEM VOL. 204, May 14, 2007  1231
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(Fig. 7 B and Fig. S2 and Videos S1 and S2, which are available 
at http://www.jem.org/cgi/content/full/jem.20070145/DC1). 
This suggested that LIMP-2 may be important for proper 
ID function by mediating the role of cadherin. Indeed, histo-
chemical analysis of cadherin in the hearts of LIMP-2 null 
mice showed aberrant cadherin distribution (Fig. 7 C) but 
normal distribution in AngII-treated WTs. AngII-treated 
WT mice show cadherin expression at the contact sites between 
two longitudinal cardiac myocytes, whereas this expression is 
less organized and more diff  use in the cardiac myocytes of 
AngII-treated LIMP-2 KO mice. This disturbed localization 
was not seen for another member of the ID, connexin 43 
(Fig. S3). These data suggest that LIMP-2 is important for the 
proper structural organization of the ID.
LIMP-2 regulates ID integrity
The functional integrity of the ID depends on the proper 
  interaction between P(Ser37)-β-catenin and cadherin (19, 20). 
Therefore, we investigated whether the absence of LIMP-2 
aff  ected the binding of P-β-catenin to cadherin. IP of cad-
herin in LV lysates of LIMP-2 KO and control mice showed 
that the absence of LIMP-2 indeed diminished the inter-
action between P-β-catenin and cadherin (Fig. 8, A and D). 
This mechanism was independently confi  rmed in another 
model of LIMP-2 inactivation in which we introduced short-
hairpin RNA (shRNA) against LIMP-2 (shLIMP-2) with a 
lentiviral vector to neonatal rat cardiac myocytes. After 10 d 
of culture, LIMP-2 protein expression was diminished by 
92% in shLIMP-2–treated cardiac myocytes as compared 
with control-treated cardiac myocytes (Fig. 8 B). Again, 
there was a diminished interaction between P-β-catenin and 
cadherin in the absence of LIMP-2 (Fig. 8, C and D). IP was 
specifi  c for cadherin (Fig. S4, available at http://www.jem
.org/cgi/content/full/jem.20070145/DC1).
To further establish the role of LIMP-2 in the binding of 
P-β-catenin to cadherin, we asked whether overexpression of 
LIMP-2 would increase the levels of cadherin-bound P-β-
catenin. Indeed, 513-fold overexpression of LIMP-2 in neo-
natal rat cardiac myocytes increased the amount of P-β-catenin 
bound to cadherin (Fig. 8, E and F), confi  rming that LIMP-2 
modulates the interaction between P-β-catenin and cadherin.
DISCUSSION
We demonstrate in this study that the lysosomal protein LIMP-2 
is an important and novel component of the cardiac myocyte 
ID, in particular adherens junctions. We show that LIMP-2 
binds to N-cadherin and that LIMP-2 null mice fail to mount 
a hypertrophic response to pressure loading but develop dilated 
cardiomyopathy upon AngII-induced hypertension, which 
Figure 6.  LIMP-2 is present at the plasma membrane of cardiac 
myocytes and is important for ID function. Light (A) and immuno-
electron (B) microscopy on a pressure-overloaded mouse, respectively. Rat 
LV tissue sections show LIMP-2 staining in intracellular compartments (*) 
and on plasma membranes of cardiac myocytes (arrows). Bars, 250 μm (A), 
respectively, 1 μm (B). Electron microscopy shows normal IDs in   AngII-
treated WT mice, whereas in AngII-treated LIMP-2 KO mice, the IDs 
have a higher degree of convolution, paralleled by the dilated cardio-
myopathy in these mice (C). Bars, 2 μm. Degree of convolution was quanti-
fi  ed (blinded) by counting the number of curves per centimeter ID on 
electron microscopic pictures and differed signifi  cantly (*, P < 10−5 vs. 
WT AngII; n = 15 for WT AngII and n = 15 for KO AngII) (D). M, mito-
chondrion; a, adherens junction; d, desmosome.
Figure 7.  LIMP-2 regulates cadherin distribution. (A) LIMP-2 binds 
to cadherin in neonatal rat ventricular myocytes. LIMP-2 was immuno-
precipitated (IP), and cadherin was immunoblotted (IB) in the total cell 
lysate (input), the supernatant (sup), and the precipitated protein lysate 
(IP). Part of the cadherin protein content of cardiac myocytes is bound by 
LIMP-2. (B) Representative tissue section of an HF patient was immuno-
fl  uorescently stained with anti–pan-cadherin (red) and anti–LIMP-2 
(green). The arrow shows colocalization of LIMP-2 and cadherin at the ID 
of cardiac myocytes. Bar, 50 μm. Tissue sections of AngII-treated LIMP-2 
KO and WT LVs were immunostained with anti–pan-cadherin (C). In WT 
mice, the cadherin distribution is confi  ned to the IDs yielding a regular 
appearance of cadherin, whereas in LIMP-2 KO mice, the localization of 
cadherin has lost the typical pattern produced by a strict location at the 
ID. Bars, 250 μm.1232  LIMP-2 CRUCIAL TO PREVENT CARDIOMYOPATHY | Schroen et al.
is accompanied by disturbed localization of N-cadherin and 
reduced affi   nity of β-catenin for N-cadherin in the heart. 
Confi  rming this in vitro, we show that knockdown of LIMP-
2 in cultured myocytes also disturbs interactions between 
N-cadherin and β-catenin, whereas LIMP-2 overexpression 
has the opposite eff  ect. This suggests that LIMP-2, which was 
initially known as a lysosomal protein, is also an important 
part of the ID and is crucial for the hypertrophic response to 
cardiac loading.
LIMP-2 is a novel mediator of ID function
LIMP-2 stands out among ID proteins. Complete loss of other 
major constituents of the ID (cadherin, β-catenin, and plako-
globin) is lethal due to the developmental cardiac derange-
ments (3–6), suggesting that these components of the ID are 
essential for normal cardiac development. In contrast, cardiac 
development is normal in LIMP-2 null mice, and loss of 
LIMP-2 only aff  ects postnatal cardiac remodeling upon hy-
pertension. This suggests that LIMP-2 represents a diff  erent 
type of ID protein, whose role is essential mainly under 
increased loading conditions. A protective role for LIMP-2 
against excessive loading is suggested by our fi  nding  that 
LIMP-2 null mice developed cardiac dilation and secondary 
excessive fi  brosis in response to pressure loading by chronic 
AngII infusion. This specifi  c role for LIMP-2 is underlined by 
our fi  nding that expression of LIMP-2 further rises in hyper-
trophied rat hearts that are on the brink of progression to HF, 
which suggests that LIMP-2 expression particularly increases 
in cardiac myocytes that are incapable of normalizing loading 
conditions. This is also underlined by our fi  nding that LIMP-2 
expression increases rapidly with pressure loading, and also in-
creases with exercise-induced physiological loading. We trans-
lated these fi  ndings to the human situation, which showed that 
LIMP-2 is also robustly increased in patients with clinically 
severe pressure loading. Collectively, we suggest that LIMP-2 
is a novel mediator of ID function and represents a hitherto 
unidentifi  ed class of mediators that are essential in the hyper-
trophic response to increased cardiac loading.
Mechanisms of LIMP-2–mediated response to loading
We documented ID abnormalities in pressure-loaded LIMP-2 
null mice. Remodeling of the ID has been shown previously 
during the transition from compensated LV hypertrophy 
  toward HF (19), whereas structural perturbations of the ID 
have been linked to dilated cardiomyopathy in humans, 
  hamsters, and pigs (2, 18, 21). We show that LIMP-2 binds 
N-cadherin, suggesting a role for LIMP-2 via this ID constit-
uent. Indeed, pressure-overloaded LIMP-2 KO mice show 
abnormal IDs on electron microscopy and their N-cadherin 
distribution is disturbed, suggesting a defect in the adherens 
junctions. The strength of adherens junctions is determined 
by the binding affi   nity between N-cadherin and β-catenin 
(22), which is regulated by phosphorylation of the latter 
(19, 20). We show in vivo as well as in vitro that loss of LIMP-2 
disturbs this N-cadherin–β-catenin complex. Given the 
linkage of adherens junctions to myofi  brils, a loss of LIMP-2 
is expected to lead to a decreased force transduction effi   ciency 
across the plasma membrane (18). The importance of the level 
of LIMP-2 is underlined by our fi  nding that in vitro over-
expression of LIMP-2 increases the binding of N-cadherin to 
β-catenin. This suggests that the increased LIMP-2 expression 
in failure-prone hypertrophy has protective purposes and is 
able to improve the N-cadherin–β-catenin interaction.
We suggest that LIMP-2 is essential for the proper binding 
of N-cadherin to β-catenin and that this role is particularly 
important under loading conditions. However, the precise 
Figure 8.  LIMP-2 regulates ID integrity by regulating the binding 
of phosphorylated 𝗃-catenin to cadherin. Immunoblot (IB) of lysates 
of neonatal rat cardiac myocytes that were treated either with shLIMP-2 
or control shRNA (B). After 10 d of culture, cardiac myocytes show a 92% 
knockdown of LIMP-2 protein. Equal protein loading was confi  rmed by 
GAPDH. Representative immunoblots (IB) show diminished levels of P-β-
catenin after IP with anti–pan-cadherin in LIMP-2 KO tissue lysates (A) as 
well as in shLIMP-2 cell lysates (C) as compared with control. P-β-catenin 
in total shLIMP-2 and control protein lysates was comparable (C). Quanti-
fi  cation of immunoblots (n = 3 per group for control and LIMP-2 KO 
tissue lysates; n = 4 per group for control and shLIMP-2 cell lysates) is 
shown in D. Overexpression of LIMP-2 in neonatal rat cardiac myo-
cytes increases levels of P-β-catenin bound to pan-cadherin (E and F). 
*, P < 0.05 versus control; **, P < 0.001 versus control.JEM VOL. 204, May 14, 2007  1233
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way by which LIMP-2 assures the binding of N-cadherin to 
β-catenin remains to be elucidated. LIMP-2 contains two 
transmembrane domains, a cytoplasmic loop and two luminal 
glycosylated domains (23). It is known that lysosomal mem-
brane proteins can shuttle between lysosomal and plasma 
membranes. A recent study by Knipper et al. (24) shows 
LIMP-2 playing a signifi  cant role in the cell surface expres-
sion of ion channels in the ear. In addition, LIMP-2 can bind 
to TSP1 (13) and TSP2 (not depicted). This latter is intriguing, 
as we have documented earlier that TSP2 is also essential for 
the response to cardiac pressure loading and increases in 
failure-prone forms of LV hypertrophy (10). This suggests that 
both LIMP-2 and TSP2 may be part of a complex that is 
needed for the cardiac myocyte to mount an adaptive response 
to loading.
Implications
We uncover a novel role for LIMP-2 as an important media-
tor of the ID when the myocardium faces increased loading 
conditions. Apart from this novel biological insight, our fi  nd-
ing that expression of LIMP-2 rises in hypertrophied rat 
hearts that are on the brink of progression to HF makes it 
tempting to speculate that increased LIMP-2 expression by 
cardiac myocytes demonstrates their inability to normalize 
loading conditions. As such, increased LIMP-2 expression 
may signify that normalization of cardiac loading conditions 
by hypertrophy has failed, and that the ID is signaling to in-
voke a continued hypertrophic response. Because we show 
that LIMP-2 expression is also robustly increased in patients 
with clinically severe pressure loading and is located at the 
plasma membrane, LIMP-2 may be an attractive target for 
molecular imaging to identify—already in a very early stage—
the myocardium that is about to succumb to the pressure.
MATERIALS AND METHODS
Ren-2 rats, microarray analysis, and immunoblotting. From 10-wk-old 
Ren-2 and Sprague-Dawley rats (Möllegard), a biopsy of the LV was taken as 
described previously (12). Rats were followed by serial echocardiography at 
10, 12, 15, 16, 18, 19, and 21 wk of age and killed at 15–18 wk upon clinical 
signs of HF (HF-prone/ HF-prone rats) or at 21 wk when clinical signs of 
failure had not appeared (compensated/compensated rats). Total RNA was 
isolated from LV biopsies and amplifi  ed as described previously (10, 25), 
hybridized to Aff  ymetrix rat RAE230 2.0 GeneChips, and analyzed with 
Microarray Analysis Suite software (version 5.0). 50 μg of LV protein extracts 
were immunoblotted with polyclonal rabbit anti–LIMP-2 (1:500; Novus 
Biologicals) and polyclonal rabbit anti-GAPDH (1:10,000; Abcam).
LIMP-2 KO mice. 10–12-wk-old male LIMP-2 KO and WT C57/Bl6 
mice weighing 20–25 g were used. To study the blood pressure eff  ects of 
AngII, arterial pressures were monitored during intravenous infusions at 
doses of 0.5, 1.5, 5, 15, and 50 ng per minute. To study the development of 
LV hypertrophy, AngII (1.5 μg/g/day; Bachem AG) was infused subcutane-
ously by osmotic minipump 2004 (Alzet) for 14 and 28 d. Echocardiography 
was performed at days 0, 7, 10, 14, and 28. At days 14 and 28, mice were 
hemodynamically monitored (dP/dt) using a Millar pressure sensor under 
basal- and dobutamin-stimulated conditions, and then LVs were removed. 
RNA was isolated with an RNeasy mini kit (QIAGEN), and SYBR Green 
quantitative RT-PCR analysis was performed on a BioRad iCycler to deter-
mine BNP, ANF, and aska expression (Table I).
LV sections were stained with Picro Sirious red and hematoxylin and eosin 
as described previously (26), or were immunohistochemically stained with 
monoclonal mouse anti–pan-cadherin (1:500; Sigma-Aldrich), monoclonal 
Table I.  List of primers for SYBR Green PCR and for shLIMP-2 production
Gene  Primer Sequence
Mouse-BNP
F 5′-G  T  T  T  G  G  G  C  T  G  T  A  A  C  G  C  A  C  T  G  A  -3′
R 5′-G  A  A  A  G  A  G  A  C  C  C  A  G  G  C  A  G  A  G  T  C  A  -3′
Mouse-ANF F 5′-A  T  T  G  A  C  A  G  G  A  T  T  G  G  A  G  C  C  C  A  G  A  G  T  -3′
R 5′-T  G  A  C  A  C  A  C  C  A  C  A  A  G  G  G  C  T  T  A  G  G  A  T  -3′
Mouse-aska F 5′-T  G  A  G  A  C  C  A  C  C  T  A  C  A  A  C  A  G  C  A  -3′
R 5′-C  C  A  G  A  G  C  T  G  T  G  A  T  C  T  C  C  T  T  C  -3′
Mouse-PPIAa F 5′-C  A  A  A  T  G  C  T  G  G  A  C  C  A  A  A  C  A  C  A  A  -3′
R 5′-G  C  C  A  T  C  C  A  G  C  C  A  T  T  C  A  G  T  C  T  -3′
Human–LIMP-2 F 5′-G  T  T  T  G  G  G  C  T  G  T  A  A  C  G  C  A  C  T  G  A  -3′
R 5′-G  A  A  A  G  A  G  A  C  C  C  A  G  G  C  A  G  A  G  T  C  A  -3′
Human-GAPDHa F 5′-A  C  C  C  A  C  T  C  C  T  C  C  A  C  C  T  T  T  G  A  C  -3′
R 5′-A  C  C  C  T  G  T  T  G  C  T  G  T  A  G  C  C  A  A  A  T  T  -3′
Rat–LIMP-2 F 5′-T  G  C  G  T  C  C  A  A  A  C  A  A  G  G  A  A  G  A  A  C  -3′
R 5′-A  A  T  C  T  C  T  T  G  G  C  C  C  C  T  C  T  T  A  A  A  A  T  A  A  -3′
Rat–PGK-1a F 5′-C  G  G  A  G  A  C  A  C  C  G  C  C  A  C  T  T  G  -3′
R 5′-A  A  G  G  C  A  G  G  A  A  A  A  T  A  C  T  A  A  A  C  A  T  T  G  C  -3′
Rat–shLIMP-2b Sense 5′-G  G  A  A  G  A  A  C  A  T  G  A  G  T  C  A  T  T  T  G  T  C  A  A  G  A  G  A 
A  A  A  T  G  A  C  T  C  A  T  G  T  T  C  T  T  C  C  T  T  T  T  T  C  -3′
Antisense 5′-T  C  G  A  G  A  A  A  A  A  G  G  A  A  G  A  A  C  A  T  G  A  G  T  C  A  T  T  T 
T  C  T  C  T  T  G  A  C  A  A  A  T  G  A  C  T  C  A  T  G  T  T  C  T  T  C  C  -3′
aHousekeeping genes: PPIA, cyclophilin A; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PGK-1, phosphoglycerate kinase 1.
bRat–shLIMP-2 oligonucleotides; hairpin structure in bold.1234  LIMP-2 CRUCIAL TO PREVENT CARDIOMYOPATHY | Schroen et al.
mouse anti–human desmin (1:50; DakoCytomation), and polyclonal rabbit 
anti–rat connexin 43 (Abcam). Ultrastructural analysis was performed by 
transmission electron microscopy as described previously (10).
LV protein extracts were immunoprecipitated with monoclonal 
mouse anti–pan-cadherin (1:100; Sigma-Aldrich) or IgG. IP lysates were 
immunoblotted with monoclonal anti–pan-cadherin (1:5,000), polyclonal 
anti–P-β-catenin (1:1,000; Ser33/37/Thr41; Cell Signaling Technology), 
and monoclonal anti–β-catenin (1:1,000; BD Transduction Laboratories).
LIMP-2 in mice with transverse aortic binding and in aortic stenosis. 
12-wk-old C57/Bl6 mice were subjected to transverse aortic binding or sham 
surgery for 1 h or 1 d. 50 μg of LV protein extracts were immunoblotted 
with LIMP-2 and GAPDH antibodies as described above.
RNA was isolated from transmural biopsies obtained from 20 aortic ste-
nosis patients and seven nonhypertrophic control patients as described previ-
ously (25), and SYBR Green quantitative PCR analysis was performed to 
determine LIMP-2 expression (Table I).
Double immunofl  uorescent stainings with rabbit anti–LIMP-2 (1:250; 
Cy2) and mouse anti–pan-cadherin (1:500; Cy3) were performed on sec-
tions of a human control and a patient that died of overt HF, as defi  ned by 
an ejection fraction of <35%. Nuclear counterparts were stained with 
Topro-3 (Invitrogen). Sections were imaged with a laser scanning confocal 
system (Leica), digitized at a fi  nal magnifi  cation of 126, and analyzed with 
Leica confocal software. The ethics committees of the Academic Hospital 
Maastricht and of University Hospital Leuven approved the study, and all 
patients gave informed consent.
Cell culture and lentiviral vectors. A rat LIMP-2 shRNA-expressing 
lentiviral vector was generated by annealing complementary shLIMP-2 
oligonucleotides (Table I) and ligating them into HpaI- and XhoI-digested 
pLL3.7 puro vector DNA (modifi  ed from a donation by L. van Parijs, 
Massachusetts Institute of Technology, Cambridge, MA). Lentiviral pro-
duction was performed by cotransfection of 3 μg shLIMP-2/pLL3.7 puro 
or empty pLL3.7puro and packaging vectors into 293FT cells by Lipo-
fectamine 2000 (Invitrogen), and virus-containing supernatant was har-
vested after 48 h.
A human LIMP-2 full-length cDNA-expressing lentiviral vector was 
generated by cloning the human LIMP-2 cDNA into XbaI- and EcoRI-
  digested pCDH1-MCS1-EF1-Puro Vector (System Biosciences). Lentiviral 
production was performed by cotransfection of 3 μg hLIMP-2/pCDH1-
MCS1-EF1-puro or empty pCDH1-MCS1-EF1-puro and packaging vec-
tors into 293FT cells by Lipofectamine 2000 (Invitrogen), and virus-containing 
supernatant was harvested after 48 h.
Rat ventricular cardiac myocytes (RCMs) were isolated by enzymatic 
disassociation of 1- to 2-d-old neonatal rats as described previously (27). 
For lentiviral infection and subsequent IP or RNA isolation, 5 × 105 
RCMs per well were plated on gelatinized six-well plates and cultured 
overnight in DMEM/M199 (4:1) media supplemented with 10% horse se-
rum, 5% newborn calf serum, glucose, gentamycin, and AraC. The next 
day, RCMs were placed on low serum media and infected with shLIMP-
2/pLL3.7, hLIMP-2/pCDH, or empty lentivirus, facilitated by polybrene 
(Sigma-Aldrich). After puromycin selection (3 μg/ml), infection effi   cien-
cies were above 80%. After 10 d of culture, cellular protein was isolated 
for IP with anti–LIMP-2 (1:100), monoclonal mouse anti–pan-cadherin 
(Sigma-Aldrich; 1:100), or IgG. IP lysates were immunoblotted as de-
scribed above.
For stretch experiments, RCMs were cultured on a collagen type I–
coated silastic membrane (Specialty Manufacturing, Inc.) and subjected to 
static, equibiaxial stretch during 6 h. RNA was isolated with an RNeasy mini 
kit (QIAGEN) for LIMP-2 SYBR Green quantitative RT-PCR (Table I).
All study protocols involving animal experiments were approved by the 
Animal Care and Use Committee of the Universiteit Maastricht and were 
performed according to the offi   cial rules formulated in the Dutch law on 
care and use of experimental animals, highly similar to those of the National 
Institutes of Health.
Statistical analyses. Data are presented as average ± SEM. The data for each 
study group were compared using the Mann-Whitney or Student’s t test where 
appropriate. P < 0.05 was considered to be statistically signifi  cant.
Online supplemental material. In Table S1, a list is presented of genes 
diff   erentially expressed in failure-prone as compared with compensated 
Ren-2 rats. The diff  erential expression of these genes precedes the devel-
opment of HF in Ren-2 rats because it is derived from cardiac biopsies 
taken at 10 wk of age, when all rats still have compensatory hypertrophy. 
In Table S2, elaborate echocardiographic data are presented of LIMP-2 WT 
and KO mice at baseline and after 14 and 28 d of AngII treatment. Fig. S1 
shows cardiac sections stained for desmin after AngII treatment in LIMP-2 
WT and KO mice. This fi  gure shows additional examples besides the ex-
ample that was given in Fig. 4. Fig. S2 presents immunofl  uorescent stain-
ings of human failing and control hearts with anti–pan-cadherin (red) and 
anti–LIMP-2 (green). This fi  gure shows additional photographs to Fig. 7. 
Fig. S3 shows normal expression of connexin 43 at the ID of AngII-treated 
LIMP-2 KO and WT mice. In Fig. S4, we show that IP in Fig. 8 is spe-
cifi  c for cadherin. Videos S1 and S2 present an interactive three-dimensional 
reconstruction of LIMP-2 bound to and colocalized with cadherin in the 
human heart. The supplemental material is available at http://www.jem
.org/cgi/conent/full/jem.20070145/DC1.
We are grateful to Dr. Jacq Cleutjens and Dr. Leon de Windt for support regarding 
the histological analyses, to Hans Duimel for his expertise in electron microscopy, 
and to Melissa Swinnen, Agnieszka Strzelecka, and Davy van Houten for surgical 
assistance. We thank Dr. Matthijs Blankesteijn for kindly providing us with 
β-catenin antibodies.
This study was supported by a VIDI grant (016.036.346) from the Netherlands 
Organisation for Scientifi  c Research (NWO) to Y.M. Pinto, by Netherlands Heart 
Foundation grant 2003T302, and by the Deutsche Forschungsgemeinschaft 
SA683/5-1 to P. Saftig. Y.M. Pinto is an established investigator of the Netherlands 
Heart Foundation.
The authors have no confl  icting fi  nancial interests.
Submitted: 17 January 2007
Accepted: 16 April 2007
R  E  F  E  R  E  N  C  E  S 
  1. Opie, L.H. 2006. Controversies in cardiology. Lancet. 367:13–14.
  2.  Perriard, J.C., A. Hirschy, and E. Ehler. 2003. Dilated cardiomyopathy: 
a disease of the intercalated disc? Trends Cardiovasc. Med. 13:30–38.
  3.  Radice, G.L., H. Rayburn, H. Matsunami, K.A. Knudsen, M. Takeichi, 
and R.O. Hynes. 1997. Developmental defects in mouse embryos lack-
ing N-cadherin. Dev. Biol. 181:64–78.
  4. Ruiz, P., V. Brinkmann, B. Ledermann, M. Behrend, C. Grund, C. 
Thalhammer, F. Vogel, C. Birchmeier, U. Gunthert, W.W. Franke, 
and W. Birchmeier. 1996. Targeted mutation of plakoglobin in mice 
reveals essential functions of desmosomes in the embryonic heart. J. Cell 
Biol. 135:215–225.
 5. Haegel, H., L. Larue, M. Ohsugi, L. Fedorov, K. Herrenknecht, and 
R. Kemler. 1995. Lack of beta-catenin aff  ects mouse development at 
gastrulation. Development. 121:3529–3537.
 6. Isac, C.M., P. Ruiz, B. Pfi   tzmaier, H. Haase, W. Birchmeier, and 
I. Morano. 1999. Plakoglobin is essential for myocardial compliance 
but dispensable for myofi  bril insertion into adherens junctions. J. Cell. 
Biochem. 72:8–15.
 7. Franz, W.M., O.J. Muller, and H.A. Katus. 2001. Cardiomyopathies: 
from genetics to the prospect of treatment. Lancet. 358:1627–1637.
  8.  Norgett, E.E., S.J. Hatsell, L. Carvajal-Huerta, J.C. Cabezas, J. 
Common, P.E. Purkis, N. Whittock, I.M. Leigh, H.P. Stevens, and 
D.P. Kelsell. 2000. Recessive mutation in desmoplakin disrupts desmo-
plakin-intermediate fi  lament interactions and causes dilated cardiomy-
opathy, woolly hair and keratoderma. Hum. Mol. Genet. 9:2761–2766.
 9. van Tintelen, J.P., M.M. Entius, Z.A. Bhuiyan, R. Jongbloed, A.C. 
Wiesfeld, A.A. Wilde, J. van der Smagt, L.G. Boven, M.M. Mannens, 
I.M. van Langen, et al. 2006. Plakophilin-2 mutations are the major JEM VOL. 204, May 14, 2007  1235
ARTICLE
determinant of familial arrhythmogenic right ventricular dysplasia/car-
diomyopathy. Circulation. 113:1650–1658.
10.  Schroen, B., S. Heymans, U. Sharma, W.M. Blankesteijn, S. Pokharel, 
J.P. Cleutjens, J.G. Porter, C.T. Evelo, R. Duisters, R.E. van Leeuwen, 
et al. 2004. Thrombospondin-2 is essential for myocardial matrix integ-
rity: increased expression identifi  es failure-prone cardiac hypertrophy. 
Circ. Res. 95:515–522.
11. Sharma, U.C., S. Pokharel, T.J. van Brakel, J.H. van Berlo, J.P. 
Cleutjens, B. Schroen, S. Andre, H.J. Crijns, H.J. Gabius, J. Maessen, 
and Y.M. Pinto. 2004. Galectin-3 marks activated macrophages in 
failure-prone hypertrophied hearts and contributes to cardiac dysfunction. 
Circulation. 110:3121–3128.
12.  van Haaften, R.I., B. Schroen, B.J. Janssen, A. van Erk, J.J. Debets, H.J. 
Smeets, J.F. Smits, A. van den Wijngaard, Y.M. Pinto, and C.T. Evelo. 
2006. Biologically relevant eff  ects of mRNA amplifi  cation on gene ex-
pression profi  les. BMC Bioinformatics. 7:200.
13. Crombie, R., and R. Silverstein. 1998. Lysosomal integral membrane 
protein II binds thrombospondin-1. Structure-function homology with 
the cell adhesion molecule CD36 defi  nes a conserved recognition motif. 
J. Biol. Chem. 273:4855–4863.
14. Eskelinen, E.L., Y. Tanaka, and P. Saftig. 2003. At the acidic edge: 
emerging functions for lysosomal membrane proteins. Trends Cell Biol. 
13:137–145.
15. Nishino, I., J. Fu, K. Tanji, T. Yamada, S. Shimojo, T. Koori, M. 
Mora, J.E. Riggs, S.J. Oh, Y. Koga, et al. 2000. Primary LAMP-2 defi  -
ciency causes X-linked vacuolar cardiomyopathy and myopathy (Danon 
disease). Nature. 406:906–910.
16. Stypmann, J., K. Glaser, W. Roth, D.J. Tobin, I. Petermann, R. 
Matthias, G. Monnig, W. Haverkamp, G. Breithardt, W. Schmahl, et al. 
2002. Dilated cardiomyopathy in mice defi  cient for the lysosomal cyste-
ine peptidase cathepsin L. Proc. Natl. Acad. Sci. USA. 99:6234–6239.
17.  Stilli, D., L. Bocchi, R. Berni, M. Zaniboni, F. Cacciani, C. Chaponnier, 
E. Musso, G. Gabbiani, and S. Clement. 2006. Correlation of alpha-
skeletal actin expression, ventricular fi  brosis and heart function with the 
degree of pressure overload cardiac hypertrophy in rats. Exp. Physiol. 
91:571–580.
18. Ferreira-Cornwell, M.C., Y. Luo, N. Narula, J.M. Lenox, M. 
Lieberman, and G.L. Radice. 2002. Remodeling the intercalated disc 
leads to cardiomyopathy in mice misexpressing cadherins in the heart. 
J. Cell Sci. 115:1623–1634.
19. Wang, X., and A.M. Gerdes. 1999. Chronic pressure overload cardiac 
hypertrophy and failure in guinea pigs: III. Intercalated disc remodeling. 
J. Mol. Cell. Cardiol. 31:333–343.
20.  Tsybouleva, N., L. Zhang, S. Chen, R. Patel, S. Lutucuta, S. Nemoto, 
G. DeFreitas, M. Entman, B.A. Carabello, R. Roberts, and A.J. Marian. 
2004. Aldosterone, through novel signaling proteins, is a fundamental 
molecular bridge between the genetic defect and the cardiac phenotype 
of hypertrophic cardiomyopathy. Circulation. 109:1284–1291.
21. Fujio, Y., F. Yamada-Honda, N. Sato, H. Funai, A. Wada, N. Awata, 
and N. Shibata. 1995. Disruption of cell-cell adhesion in an inbred strain 
of hereditary cardiomyopathic hamster (Biol. 14.6). Cardiovasc. Res. 
30:899–904.
22.  Gumbiner, B.M. 2000. Regulation of cadherin adhesive activity. J. Cell 
Biol. 148:399–404.
23.  Gamp, A.C., Y. Tanaka, R. Lullmann-Rauch, D. Wittke, R. D’Hooge, 
P.P. De Deyn, T. Moser, H. Maier, D. Hartmann, K. Reiss, et al. 2003. 
LIMP-2/LGP85 defi  ciency causes ureteric pelvic junction obstruction, deaf-
ness and peripheral neuropathy in mice. Hum. Mol. Genet. 12:631–646.
24.  Knipper, M., C. Claussen, L. Ruttiger, U. Zimmermann, R. Lullmann-
Rauch, E.L. Eskelinen, J. Schroder, M. Schwake, and P. Saftig. 2006. 
Deafness in LIMP2-defi  cient mice due to early loss of the potassium 
channel KCNQ1/KCNE1 in marginal cells of the stria vascularis. 
J. Physiol. 576:73–86.
25.  Heymans, S., B. Schroen, P. Vermeersch, H. Milting, F. Gao, A. Kassner, 
H. Gillijns, P. Herijgers, W. Flameng, P. Carmeliet, et al. 2005. Increased 
cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue 
inhibitor of metalloproteinase-2 is related to cardiac fi  brosis and dys-
function in the chronic pressure-overloaded human heart. Circulation. 
112:1136–1144.
26. Junqueira, L.C., G. Bignolas, and R.R. Brentani. 1979. Picrosirius 
staining plus polarization microscopy, a specifi  c method for collagen 
detection in tissue sections. Histochem. J. 11:447–455.
27.  De Windt, L.J., P.H. Willemsen, S. Popping, G.J. Van der Vusse, R.S. 
Reneman, and M. Van Bilsen. 1997. Cloning and cellular distribution 
of a group II phospholipase A2 expressed in the heart. J. Mol. Cell. 
Cardiol. 29:2095–2106.